Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression ...
The company describes KSI-101 as a “novel, potent, and high-strength (100 mg/mL) antibody-based investigational therapy with ...
New York, NY, May 07, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The subretinal gene therapy injection ...
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of ...
December Cartoon Caption Contest: The Stone Age Rocks! Mix some Stone Age cavemen and cave drawings of a hunter, and what does that say about early medicine? Find out what our readers thought in this ...
Uniting clinical leaders and industry innovators to tackle significant challenges in the dry eye market. With the rising prevalence of dry eye disease, the shortcomings of existing treatments, as well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback